Loading organizations...
Chase Pharmaceuticals: Clinical-stage biopharmaceutical company developing improved treatments for neurodegenerative disorders, focused on Alzheimer's disease.
Chase Pharmaceuticals was a clinical-stage biopharmaceutical company developing improved treatments for neurodegenerative disorders like Alzheimer's disease. The enterprise focused on enhancing the efficacy and safety of existing central nervous system therapeutics, specifically targeting established drugs such as ARICEPT and Exelon. By advancing its lead clinical candidate, CPC-201, the organization aimed to provide superior symptomatic relief for affected patients. Before its exit, the business secured over $24 million in venture capital funding from a syndicate of lead investors that included New Rhein Healthcare Investors, Edmond de Rothschild, and Cipla Ventures. Under the leadership of chief executive officer Douglas Ingram, the pharmaceutical giant Allergan acquired the company in 2016 for an upfront payment of $125 million, alongside milestone agreements potentially totaling up to $1 billion. Chase Pharmaceuticals was founded in 2007 by Thomas Chase and Kathleen Clarence-Smith.
Chase Pharmaceuticals has raised $24.0M across 2 funding rounds.
Chase Pharmaceuticals has raised $24.0M in total across 2 funding rounds.
Chase Pharmaceuticals has raised $24.0M in total across 2 funding rounds.
Chase Pharmaceuticals's investors include Cipla, Greg Parekh, Brain Trust Accelerator Fund II, Vikram Sudarsan.
Chase Pharmaceuticals has raised $24.0M across 2 funding rounds. Most recently, it raised $3.0M Other Equity in March 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 16, 2016 | $3.0M Other Equity | Cipla | |
| May 12, 2014 | $21.0M Series B | Greg Parekh | Brain Trust Accelerator Fund II, Vikram Sudarsan |